title: Maximum standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas.
abstract: OBJECTIVE
  The purpose of this study was to assess the correlations among the maximum standardized uptake value (SUVmax) on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (FDG-PET/CT); the expressions of glucose transporter 1 (GLUT-1), glucose transporter 3, and epidermal growth factor receptor (EGFR); as well as prognosis in patients with invasive ductal carcinoma of the pancreas.
  
  
  METHODS
  A total of 41 patients with surgically resected and histologically proven invasive ductal carcinoma of the pancreas who underwent preoperative FDG-PET/CT were assessed. The SUVmax at the primary tumor site was measured by FDG-PET/CT, and immunohistochemical staining of tumor sections was performed for GLUT-1, glucose transporter 3, and EGFR.
  
  
  RESULTS
  Higher FDG uptake (SUVmax, >3.40) and GLUT-1 expression were significantly associated with shorter overall survival (P < 0.05). The SUVmax was not found to be significantly correlated with clinicopathological characteristics such as TNM classification, lymph node metastasis, and tumor differentiation. The EGFR expression was significantly correlated with the SUVmax (P = 0.024).
  
  
  CONCLUSIONS
  Higher FDG uptake and GLUT-1 expression in invasive ductal carcinoma of the pancreas seems to be an important prognostic factor. In addition, the EGFR expression was significantly correlated with the SUVmax.
authors.affiliation: From the Departments of *Surgery, †Internal Medicine (Division of Gastroenterology), ‡Hospital Pathology, and §Radiology, Kurume University School of Medicine, Kurume, Japan.
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Kitasato
authors.forename: Masafumi
authors.initials: M
authors.lastname: Yasunaga
authors.forename: Koji
authors.initials: K
authors.lastname: Okuda
authors.forename: Hisafumi
authors.initials: H
authors.lastname: Kinoshita
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Okabe
authors.forename: Akihiko
authors.initials: A
authors.lastname: Kawahara
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Kage
authors.forename: Hayato
authors.initials: H
authors.lastname: Kaida
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Ishibashi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D021441:Carcinoma, Pancreatic Ductal / Q000737:chemistry / Q000000981:diagnostic imaging* / Q000401:mortality / Q000601:surgery; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics*; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D051272:Glucose Transporter Type 1 / Q000032:analysis*; D051274:Glucose Transporter Type 3 / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009363:Neoplasm Proteins / Q000032:analysis*; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000000981:diagnostic imaging* / Q000401:mortality / Q000601:surgery; D016577:Pancreaticoduodenectomy; D049268:Positron-Emission Tomography; D011300:Preoperative Care; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D012189:Retrospective Studies; D016037:Single-Blind Method; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed
chemical_list: D005462:Fluorine Radioisotopes; D051272:Glucose Transporter Type 1; D051274:Glucose Transporter Type 3; D009363:Neoplasm Proteins; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C512478:EGFR protein, human; D066246:ErbB Receptors